Related Experiment Video
Updated: Mar 19, 2026

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
The Current and Evolving Role of PET in Personalized Management of Lung Cancer
Esther Mena1, Anusha Yanamadala1, Gang Cheng2
1Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA.
Abstract:
Using tumor genomic profiling information has revolutionized the landscape of personalized treatment of lung cancer. The management of lung cancer and non-small cell lung cancer particularly is influenced by discoveries of activating mutations in epidermal growth factor receptor and targeted therapies with tyrosine kinase inhibitors, fusion genes involving anaplastic lymphoma kinase, and targeted therapies for Kristen-Rat-Sarcoma and MET protooncogenes. PET imaging plays an important role in assessing the biologic behavior of lung cancer and defining response to therapy. This review summarizes genomic discoveries in lung cancer and their implications for functional PET imaging.
Insights
Genomic profiling transformed lung cancer treatment, guiding targeted therapies for mutations like EGFR and ALK. This review explores these genomic advances and their impact on positron emission tomography (PET) imaging for lung cancer.
Area of Science:
- Oncology
- Genetics
- Radiology
Background:
- Personalized treatment of lung cancer is increasingly driven by tumor genomic profiling.
- Key discoveries include epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) fusions, and Kristen-Rat-Sarcoma (KRAS)/MET protooncogene alterations.
- Positron emission tomography (PET) imaging is vital for assessing lung cancer biology and treatment response.
Purpose of the Study:
- To review significant genomic discoveries in lung cancer.
- To discuss the implications of these genomic findings for functional PET imaging.
Main Methods:
- Literature review of genomic discoveries in lung cancer.
- Analysis of the role of PET imaging in relation to these genomic alterations.
Main Results:
- Genomic profiling has identified actionable targets, revolutionizing non-small cell lung cancer (NSCLC) treatment.
- Targeted therapies (e.g., tyrosine kinase inhibitors) have emerged based on these discoveries.
- PET imaging can reflect the biological behavior influenced by these genomic changes.
Conclusions:
- Genomic discoveries are fundamentally changing lung cancer management.
- Integrating genomic information with PET imaging offers new avenues for personalized therapy assessment and monitoring in lung cancer.
Related Concept Videos
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

